Using continuous glucose monitoring to identify diabetes risk in cystic fibrosis patients
Official title: Identification of Dysglycemia With Continuous Glucose Monitoring: A Prospective Study to Assess the Relationship With Clinical Evolution in Cystic Fibrosis
Run by Institut de Recherches Cliniques de Montreal · NCT05099939 · Data updated 2026-11-12
This study is testing if continuous glucose monitoring can help find out which cystic fibrosis patients are at risk for diabetes by tracking their health over five years.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 121 (estimated) |
| Sponsor | Institut de Recherches Cliniques de Montreal Academic / other |
| Locations | 4 sites (Montreal, Quebec and 3 other locations) |
| Status | Recruiting |
| Started | November 25, 2021 |
| Main results expected | July 2026 |
| Study ends | July 2026 |
| Registry record updated | November 6, 2024 |
| Trial ID | NCT05099939 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older diagnosed with cystic fibrosis.
✕Probably not a fit
Patients who are currently receiving pharmaceutical treatment for diabetes or have had a lung or liver transplant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the predictive value of continuous glucose monitoring (CGM) in assessing the clinical evolution of adult patients with cystic fibrosis (CF). Over a period of five years, the study will track the clinical condition of participants, including lung function and nutritional status, while collecting detailed glycemic profiles through CGM at three different visits. The primary goal is to identify CGM variables that correlate with a decline in pulmonary function and other clinical markers. This approach seeks to provide a less invasive and more effective alternative to the standard oral glucose tolerance test for screening diabetes in CF patients.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection and management of diabetes in cystic fibrosis patients, potentially reducing morbidity and mortality associated with the condition.
How similar studies have gone: While the use of continuous glucose monitoring in other populations has shown promise, this specific application in cystic fibrosis is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have cystic fibrosis * Be 18 years of age or older * Have given clear and informed consent Exclusion Criteria: * Receive pharmaceutical treatment for diabetes * Have had a lung or liver transplant * Participate in a randomized controlled trial for more than 3 months in parallel with this study * Currently pregnant * Patients under legal protection (for centers in France)
Where it's running
-
Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada Recruiting -
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada Not yet recruiting -
Hospices Civils de Lyon
Lyon, France Not yet recruiting -
CHU de Strasbourg
Strasbourg, France Not yet recruiting
Study contacts
- Principal investigator: Rémi Rabasa-Lhoret — Institut de Recherches Cliniques de Montreal
- Study coordinator: Katherine Desjardins
- Email: katherine.desjardins@ircm.qc.ca
- Phone: 5149875666
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older
This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.
-
VX-272 dose escalation in healthy adults
This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.
-
Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis
This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.
-
Dose escalation of VX-581 to check safety and drug levels in healthy adults
The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.
-
PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care
This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.
-
Collecting sputum samples at home for cystic fibrosis patients
This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.